$RNAC
Cartesian Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000119312523214708 Filed on August 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $6.551M $5.249M
YoY Change -68.37% -86.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.614M $6.105M
YoY Change 14.63% -2.02%
% of Gross Profit
Research & Development $13.00M $17.78M
YoY Change -21.39% -7.3%
% of Gross Profit
Depreciation & Amortization $100.0K $200.0K
YoY Change -50.0% 0.0%
% of Gross Profit
Operating Expenses $19.62M $23.89M
YoY Change -12.07% -6.0%
Operating Profit -$13.07M -$18.64M
YoY Change 717.07% -234.47%
Interest Expense $1.273M $752.0K
YoY Change 58.73% 5.17%
% of Operating Profit
Other Income/Expense, Net $253.0K $245.0K
YoY Change 25200.0%
Pretax Income -$9.002M -$11.39M
YoY Change 9.59% -232.39%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.002M -$11.39M
YoY Change 14.05% -232.39%
Net Earnings / Revenue -137.41% -216.94%
Basic Earnings Per Share -$0.06 -$0.07
Diluted Earnings Per Share -$0.06 -$0.07
COMMON SHARES
Basic Shares Outstanding 153.4M 153.4M shares
Diluted Shares Outstanding 154.8M 153.4M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.60M $112.0M
YoY Change -45.64% -21.14%
Cash & Equivalents $79.60M $112.0M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $3.493M $4.258M
YoY Change -44.64% -34.71%
Inventory
Prepaid Expenses
Receivables $4.898M $5.385M
Other Receivables $1.875M $1.055M
Total Short-Term Assets $89.87M $122.7M
YoY Change -43.72% -28.88%
LONG-TERM ASSETS
Property, Plant & Equipment $2.421M $2.593M
YoY Change -16.63% -8.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.000M $2.000M
YoY Change 0.0% 0.0%
Other Assets $1.405M $1.413M
YoY Change -13.7% -0.84%
Total Long-Term Assets $16.17M $16.78M
YoY Change -13.04% 8.29%
TOTAL ASSETS
Total Short-Term Assets $89.87M $122.7M
Total Long-Term Assets $16.17M $16.78M
Total Assets $106.0M $139.5M
YoY Change -40.52% -25.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $375.0K $267.0K
YoY Change 75.23% -61.47%
Accrued Expenses $13.64M $12.90M
YoY Change 11.2% 4.33%
Deferred Revenue $4.140M $4.234M
YoY Change 8.38% -73.49%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $10.24M
YoY Change -100.0% 211.57%
Total Short-Term Liabilities $19.94M $29.37M
YoY Change -15.97% -13.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $13.79M
YoY Change -100.0% -39.09%
Other Long-Term Liabilities $25.77M $30.90M
YoY Change -47.86% -26.53%
Total Long-Term Liabilities $25.77M $44.69M
YoY Change -63.0% -30.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.94M $29.37M
Total Long-Term Liabilities $25.77M $44.69M
Total Liabilities $45.71M $74.06M
YoY Change -51.04% -24.79%
SHAREHOLDERS EQUITY
Retained Earnings -$437.0M -$428.0M
YoY Change 9.02% 8.92%
Common Stock $15.00K $15.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $60.33M $65.45M
YoY Change
Total Liabilities & Shareholders Equity $106.0M $139.5M
YoY Change -40.52% -25.82%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$9.002M -$11.39M
YoY Change 14.05% -232.39%
Depreciation, Depletion And Amortization $100.0K $200.0K
YoY Change -50.0% 0.0%
Cash From Operating Activities -$9.215M -$9.895M
YoY Change -311.69% -19.36%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $12.00K
YoY Change -100.0% -112.12%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$12.00K
YoY Change -100.0% -87.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -24.79M -2.586M
YoY Change -4150.49% -107.01%
NET CHANGE
Cash From Operating Activities -9.215M -9.895M
Cash From Investing Activities 0.000 -12.00K
Cash From Financing Activities -24.79M -2.586M
Net Change In Cash -34.00M -12.49M
YoY Change 36.17% -150.98%
FREE CASH FLOW
Cash From Operating Activities -$9.215M -$9.895M
Capital Expenditures $0.00 $12.00K
Free Cash Flow -$9.215M -$9.907M
YoY Change -292.42% -18.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001453687
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37798
dei Entity Registrant Name
EntityRegistrantName
Selecta Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1622110
dei Entity Address Address Line1
EntityAddressAddressLine1
65 Grove Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
923-1400
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SELB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
153427571
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112027000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106438000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28164000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5385000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6596000
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1055000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3162000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4258000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3778000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
122725000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
148138000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2593000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2794000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10775000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11617000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1377000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1311000
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
2000000
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
2000000
CY2023Q2 us-gaap Other Assets
OtherAssets
36000
CY2022Q4 us-gaap Other Assets
OtherAssets
26000
CY2023Q2 us-gaap Assets
Assets
139506000
CY2022Q4 us-gaap Assets
Assets
165886000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
267000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
316000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12902000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14084000
CY2023Q2 us-gaap Loans Payable Current
LoansPayableCurrent
10235000
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
8476000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1729000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1608000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4234000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
593000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
29367000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25077000
CY2023Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
13787000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
17786000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9163000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10055000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4863000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
16878000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
19140000
CY2023Q2 us-gaap Liabilities
Liabilities
74058000
CY2022Q4 us-gaap Liabilities
Liabilities
72058000
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153427571
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153427571
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153042435
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153042435
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
15000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
498016000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
493308000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-427987000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394937000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4596000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4558000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
65448000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
93828000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139506000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165886000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5249000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39273000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11187000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73272000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17782000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19182000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36406000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36871000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6105000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6231000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11800000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11768000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
23887000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
25413000
us-gaap Operating Expenses
OperatingExpenses
48206000
us-gaap Operating Expenses
OperatingExpenses
48639000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18638000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
13860000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37019000
us-gaap Operating Income Loss
OperatingIncomeLoss
24633000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1394000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
207000
us-gaap Investment Income Net
InvestmentIncomeNet
2725000
us-gaap Investment Income Net
InvestmentIncomeNet
222000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
23000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-104000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-76000
CY2023Q2 us-gaap Interest Expense
InterestExpense
752000
CY2022Q2 us-gaap Interest Expense
InterestExpense
715000
us-gaap Interest Expense
InterestExpense
1560000
us-gaap Interest Expense
InterestExpense
1422000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6341000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4647000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2262000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13868000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
245000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
500000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
154000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11387000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
8601000
us-gaap Net Income Loss
NetIncomeLoss
-33050000
us-gaap Net Income Loss
NetIncomeLoss
37379000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
118000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-49000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
86000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11414000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8719000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33088000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
37465000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153442413
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148505729
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153396380
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136436316
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153442413
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148505729
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153396380
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136966312
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
93828000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
149000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2276000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-21663000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74579000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2283000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11387000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
65448000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22521000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
127000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1675000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-79000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2753000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-32000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
28778000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
55764000
CY2022Q2 selb Stock Issued During The Period Values Common Stock And Warrants
StockIssuedDuringThePeriodValuesCommonStockAndWarrants
21480000
CY2022Q2 selb Stock Issued During The Period Values Common Stock License Agreement
StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement
1000000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
79000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2564000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
118000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
8601000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
89606000
us-gaap Net Income Loss
NetIncomeLoss
-33050000
us-gaap Net Income Loss
NetIncomeLoss
37379000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
382000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
696000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
79000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
842000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
591000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
147000
us-gaap Share Based Compensation
ShareBasedCompensation
6059000
us-gaap Share Based Compensation
ShareBasedCompensation
6317000
us-gaap Paid In Kind Interest
PaidInKindInterest
533000
us-gaap Paid In Kind Interest
PaidInKindInterest
579000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2262000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13868000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1211000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14080000
selb Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current
IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent
-2107000
selb Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current
IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-815000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
374000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-49000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
300000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-280000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8504000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-42213000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3673000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
965000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18660000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24135000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
28254000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
10000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
142000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
554000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28112000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9446000
us-gaap Repayments Of Debt
RepaymentsOfDebt
2586000
us-gaap Repayments Of Debt
RepaymentsOfDebt
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
110000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
36890000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
149000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
127000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2437000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38603000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-49000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6966000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24000000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108038000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115436000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115004000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139436000
us-gaap Interest Paid Net
InterestPaidNet
1242000
us-gaap Interest Paid Net
InterestPaidNet
1014000
selb Issuance Of Common Stock License Agreement In Stock Based Compensation Expense
IssuanceOfCommonStockLicenseAgreementInStockBasedCompensationExpense
0
selb Issuance Of Common Stock License Agreement In Stock Based Compensation Expense
IssuanceOfCommonStockLicenseAgreementInStockBasedCompensationExpense
1000000
selb Stock Based Compensation Expense In Accrued Liabilities
StockBasedCompensationExpenseInAccruedLiabilities
1500000
selb Stock Based Compensation Expense In Accrued Liabilities
StockBasedCompensationExpenseInAccruedLiabilities
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
48000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
320000
selb Equity Offering Costs In Accrued Liabilities
EquityOfferingCostsInAccruedLiabilities
0
selb Equity Offering Costs In Accrued Liabilities
EquityOfferingCostsInAccruedLiabilities
31000
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.25
CY2023Q2 selb Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale
115000000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3000000
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
251000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
28175000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
28164000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11387000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
8601000
us-gaap Net Income Loss
NetIncomeLoss
-33050000
us-gaap Net Income Loss
NetIncomeLoss
37379000
CY2023Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
CY2022Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
13868000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11387000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11387000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
8601000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
8601000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33050000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33050000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
23511000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
23511000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153442413
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
148505729
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153396380
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136436316
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
529996
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153442413
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148505729
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153396380
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136966312
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53835968
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47729897
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53835968
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37524598
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112027000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138057000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1600000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1377000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1379000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115004000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
139436000
us-gaap Operating Lease Cost
OperatingLeaseCost
1392000
us-gaap Operating Lease Cost
OperatingLeaseCost
1011000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
270000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
205000
us-gaap Variable Lease Cost
VariableLeaseCost
412000
us-gaap Variable Lease Cost
VariableLeaseCost
425000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
2000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8167000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7999000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5574000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5205000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2593000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2794000
CY2022Q2 us-gaap Depreciation
Depreciation
200000
CY2023Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
300000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
2000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2978000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4242000
CY2023Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2523000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
CY2023Q2 selb Accrued Patent Fees Current
AccruedPatentFeesCurrent
471000
CY2022Q4 selb Accrued Patent Fees Current
AccruedPatentFeesCurrent
696000
CY2023Q2 selb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5094000
CY2022Q4 selb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
7274000
CY2023Q2 selb Accrued Audit Fees Current
AccruedAuditFeesCurrent
1257000
CY2022Q4 selb Accrued Audit Fees Current
AccruedAuditFeesCurrent
985000
CY2023Q2 selb Accrued Interest Current
AccruedInterestCurrent
187000
CY2022Q4 selb Accrued Interest Current
AccruedInterestCurrent
222000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
392000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
665000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12902000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14084000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
696000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
505000
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
0
us-gaap Sublease Income
SubleaseIncome
506000
us-gaap Sublease Income
SubleaseIncome
0
CY2023Q2 us-gaap Lease Cost
LeaseCost
717000
CY2022Q2 us-gaap Lease Cost
LeaseCost
712000
us-gaap Lease Cost
LeaseCost
1303000
us-gaap Lease Cost
LeaseCost
1441000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1349000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2740000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2818000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2902000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2990000
CY2023Q2 selb Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
946000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13745000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2853000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
10892000
us-gaap Operating Lease Payments
OperatingLeasePayments
1319000
us-gaap Operating Lease Payments
OperatingLeasePayments
924000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.097
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
31228279
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.53
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
63167349
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3783000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3564000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6059000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6317000
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
9100000
CY2022Q4 selb Contractwith Customer Liability Deferred Revenue
ContractwithCustomerLiabilityDeferredRevenue
593000
selb Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts
ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts
10500000
selb Contractwith Customer Liability Deferred Revenue Revenue Recognized
ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized
-1996000
CY2023Q2 selb Contractwith Customer Liability Deferred Revenue
ContractwithCustomerLiabilityDeferredRevenue
9097000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
593000
selb Contractwith Customer Liability Increase From Cash Receipts
ContractwithCustomerLiabilityIncreaseFromCashReceipts
10500000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-1996000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
9097000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
62400000
CY2022 selb Net Operating Losses Percentage Eligible To Be Carried Forward
NetOperatingLossesPercentageEligibleToBeCarriedForward
0.80
CY2022 selb Research Tax Credits Amount Eligible To Be Carried Forward
ResearchTaxCreditsAmountEligibleToBeCarriedForward
0.75
selb Defined Contribution Plan Employers Matching Contribution Vesting Period
DefinedContributionPlanEmployersMatchingContributionVestingPeriod
P2Y
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000

Files In Submission

Name View Source Status
0001193125-23-214708-index-headers.html Edgar Link pending
0001193125-23-214708-index.html Edgar Link pending
0001193125-23-214708.txt Edgar Link pending
0001193125-23-214708-xbrl.zip Edgar Link pending
d536571d10q.htm Edgar Link pending
d536571dex311.htm Edgar Link pending
d536571dex312.htm Edgar Link pending
d536571dex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
d536571d10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
selb-20230630.xsd Edgar Link pending
Show.js Edgar Link pending
selb-20230630_cal.xml Edgar Link unprocessable
selb-20230630_lab.xml Edgar Link unprocessable
selb-20230630_def.xml Edgar Link unprocessable
selb-20230630_pre.xml Edgar Link unprocessable